Trevi Therapeutics
TRVI
TRVI
63 hedge funds and large institutions have $70.2M invested in Trevi Therapeutics in 2023 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 26 increasing their positions, 14 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
34% less capital invested
Capital invested by funds: $106M → $70.2M (-$35.9M)
50% less call options, than puts
Call options by funds: $2K | Put options by funds: $4K
Holders
63
Holding in Top 10
–
Calls
$2K
Puts
$4K
Top Buyers
| 1 | +$1.46M | |
| 2 | +$1.22M | |
| 3 | +$1.11M | |
| 4 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$670K |
| 5 |
Renaissance Technologies
New York
|
+$637K |
Top Sellers
| 1 | -$11.3M | |
| 2 | -$230K | |
| 3 | -$108K | |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$85.1K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$54.7K |